Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis

Authors

  • Tatyana Ivko National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018, Ukraine
  • Tamara Germanyuk National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018, Ukraine

DOI:

https://doi.org/10.15587/2313-8416.2014.32109

Keywords:

diabetes mellitus, retrospective analysis, monotherapy, cost-effectiveness analysis, sensitivity analysis

Abstract

Research was conducted to scientific justification of rational choice of monotherapy diabetes mellitus (DM) type 2 based on the pharmacoeconomical analysis. It has been found that the unit of efficiency was the cheapest in the scheme of the monotherapy with gliclazide and most expensive – in the scheme of the monotherapy with metformin.

Author Biographies

Tatyana Ivko, National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018

Assistant

Pharmacy Department

Tamara Germanyuk, National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018

MD, professor of Ukraine, Russia and Kazakhstan

Pharmacy Department

References

Dovidnik osnovnih pokaznikiv diyalnosti endokrinologichnoyi sluzhbi Ukrayini za 2011, 2012, 2013.

Nakaz MOZ Ukrayini vid 21.12.2012 N 1118 «Unifikovaniy klinichniy protokol pervinnoyi ta vtorinnoyi (spetsializovanoyi) medichnoyi dopomogi».

Nathan, D. M., Buse, J. B., Davidson, M. B. et al. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiationand adjustment of therapy. Diabetes Care, 32 (1), 193–203. doi: 10.2337/dc08-2195

Dedov, I. I., Shestakova, M. V., Ametov, A. S. et. al. (2011). Konsensus soveta ekspertov Rossiyskoy assotsiatsii endokrinologov po initsiatsii i intensifikatsii saharosnizhayushchey terapii u bolnyh saharnym diabetom 2 tipa. Normativnye dokumenty. Saharnyy diabet, 4, 7–17

Zherdova, N. M. (2014). Individualniy pidhid do likuvannya hvorih na tsukroviy diabet 2-go tipu. Ukrayinskiy medichniy chasopis, 1 (99), 37–40.

Yagudinа, R. I., Kulikov, A. Yu., Arinina, E. E. (2011). Farmakoekonomika saharnogo diabeta vtorogo tipa. Moscow: OOO «Meditsinskoe informatsionnoe agentstvo», 64–66.

Pravinkumar, I., Тalelem, G. (2012). Adverse effects of metformin in combination with glimepiride and glibenclamide in patients with type 2 diabetes mellitus. Asian Journal of Pharmaceutical and Clinical Research, 5, 108–110.

Yakovleva, L. V., Kirichenko, O. N. (2011). Farmakoepidemiologichne i farmakoekonomicheskiy otsinka likuvannya diabetu. Klinichna endokrinologiya ta endokrinna hirurgiya, 2, 10–20.

Abdulganiyu, G., Fola, T. (2014). Cost-cost analysis of anti-diabetic therapy in a tertiary healthcare. International journal of pharmacy and pharmaceutical sciences, 6, 281–286.

Guidelines for ATC classification and DDD assignment 2013 р.15electronic resource. Available at: www.whocc.no/atc_ddd_index

Register wholesale prices of medicines electronic resource. Available at: www.moz.gov.ua/ua/register_prices_drugs

Downloads

Published

2014-12-22

Issue

Section

Pharmaceutical Sciences